In a resounding vote of confidence in China's biotechnology sector, leading global pharmaceutical companies are striking ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with ...

In May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio. That is the largest such deal this year and could be worth up to $6 billion in ...

China's biotechnology stocks have experienced a significant rally, outperforming AI, with a 60% surge since January due to billion-dollar foreign licensing deals.

The surge in China-listed biotech firms is further evidence that the mainland is becoming a center for global innovation ...

Biopharma deal activity continued its record-breaking pace in 2025, reaching $103.76 billion in total value through the first five months, the highest year-to-date total in BioWorld’s records. That ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. Otsuka detailed its phase 3 data in the kidney disease immunoglobulin A nephropathy (IgAN).

Hong Kong stocks opened down by 100 points before fluctuating, at one point briefly turning positive. At midday, the HSI stood at 23,864, down 28 points or 0.1%, with main board turnover close to HKD ...

U.S. drug companies are increasingly licensing experimental medicines invented by Chinese firms. Recent deals could be worth up to $25 billion.

3SBio, which licensed Pfizer’s rights to SSGJ-707 for $1.25 billion upfront, presented mid-stage study data in a poster session that hinted at the drug’s promise in non-small cell lung cancer.